ECM
DFTX

ExodusPoint Capital Management’s Definium Therapeutics DFTX Stock Holding History

ExodusPoint Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104,915
Closed -$1.98M – 1876
2026
Q1 		$1.98M Buy
104,915
+85,967
+454% +$1.46M 0.02% 786
2025
Q4 		$254K Buy
+18,948
New +$234K ﹤0.01% 1348
2025
Q3 		– Sell
-17,877
Closed -$116K – 1842
2025
Q2 		$116K Buy
+17,877
New +$118K ﹤0.01% 1348

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ExodusPoint Capital Management's DFTX Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 104,915 shares — an estimated $1.98M sold.

ExodusPoint Capital Management first reported a position in DFTX in Q2 2025 and held it in 3 quarters. The position peaked at $1.98M in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 104,915 Definium Therapeutics shares in Q2 2026, an estimated $1.98M.
  • ExodusPoint Capital Management first reported a position in Definium Therapeutics in Q2 2025 and held it in 3 quarters.
  • ExodusPoint Capital Management's Definium Therapeutics position peaked at $1.98M in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.